Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

5.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 Next >
Earnings Review: Bayer To Make Strategic Changes After Q3 Results
The latest financial statements from Bayer Group show a year-over-year decline in several key areas, painting a stark picture of the company’s fiscal health. 
Via Talk Markets
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
Exposures Glyphosate
Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
Investors tend to closely watch which Cathie Wood stocks are bought and sold as she has history of generating big returns in her ETFs 
Via InvestorPlace
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Daily Stock Analysis: Bayer AG - May '23 Update
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as over the counter products. 
Via Talk Markets
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
Exposures Product Safety
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
Exposures Product Safety
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tiziana Life Sciences, Inc. 
Via Benzinga
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,... 
Via Benzinga
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in... 
Via Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters
Via Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
Via Benzinga
There’s Only One Way To Beat The Market
The way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. Today, I want to show you how savvy stock pickers can profit from... 
Via Talk Markets
Perrigo Picks Former Bayer Executive As New CEO
Perrigo Co PLC (NYSE: PRGO) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors, 
Via Benzinga
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present... 
Via Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Via Benzinga
After That Big Merger, What Happened?
There are often substantial controversies over whether a merger should be allowed to happen, but then relatively little follow-up after the event. 
Via Talk Markets
InvestorNewsBreaks – ROTH MKM’s Agribusiness Investment Banking Group Serves as Sellside Advisor for Three M&A Transactions
Via Investor Brand Network
Topics Derivatives
Exposures Derivatives
Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories
Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning 
Via Benzinga
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.